<code id='11DD822AE4'></code><style id='11DD822AE4'></style>
    • <acronym id='11DD822AE4'></acronym>
      <center id='11DD822AE4'><center id='11DD822AE4'><tfoot id='11DD822AE4'></tfoot></center><abbr id='11DD822AE4'><dir id='11DD822AE4'><tfoot id='11DD822AE4'></tfoot><noframes id='11DD822AE4'>

    • <optgroup id='11DD822AE4'><strike id='11DD822AE4'><sup id='11DD822AE4'></sup></strike><code id='11DD822AE4'></code></optgroup>
        1. <b id='11DD822AE4'><label id='11DD822AE4'><select id='11DD822AE4'><dt id='11DD822AE4'><span id='11DD822AE4'></span></dt></select></label></b><u id='11DD822AE4'></u>
          <i id='11DD822AE4'><strike id='11DD822AE4'><tt id='11DD822AE4'><pre id='11DD822AE4'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:7
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In